Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Likarda Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, ARNOLD, ERNST V, who is the busiest examiner for the portfolio. The prosecution is conducted within a distinct art unit, ensuring that the application is reviewed by a department with relevant technical expertise.
With ARNOLD, ERNST V as the only examiner responsible for the pending action, the company can develop a highly consistent approach to its patent prosecution. The practitioner should focus on the specific preferences and examination history of the busiest examiner to improve the efficiency of the response. This level of concentration within the Biotechnology & Pharmaceuticals sector can lead to more predictable outcomes.
The presence of the pending office action in a distinct art unit indicates a focused patent strategy for the company. By understanding the standards and practices of this specific unit, the practitioner can better anticipate the types of objections that may arise during the review. Monitoring the progress of the pending action is essential for the successful management of the company's intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717569 | HYDROGEL MICROPARTICLE-BASED SOFT TISSUE FILLERS | ARNOLD, ERNST V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717569 | HYDROGEL MICROPARTICLE-BASED SOFT TISSUE FILLERS | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717569 | HYDROGEL MICROPARTICLE-BASED SOFT TISSUE FILLERS | ARNOLD, ERNST V | 1613 | §103§112Other | Non-Final OA | — | Pending | Jun 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLikarda Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ernst V Arnold has the most, with 1 of Likarda Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.